Morgan Stanley Call 190 ABBV 21.0.../ DE000MB9SUZ0 /
| 5/14/2024 8:26:53 AM | Chg.-0.090 | Bid12:15:43 PM | Ask12:15:43 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.310EUR | -22.50% | 0.310 Bid Size: 100 |
0.660 Ask Size: 100 |
AbbVie Inc | 190.00 USD | 6/21/2024 | Call |
GlobeNewswire
9:00 AM
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
12:14 AM
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
5/9
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
5/8
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
5/8
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
5/8
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/7
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/2
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...
GlobeNewswire
5/1
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
4/30
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire
4/30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
4/25
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
